Smoking affects the interferon beta treatment response in multiple sclerosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Smoking affects the interferon beta treatment response in multiple sclerosis. / Petersen, Eva R; Oturai, Annette B; Koch-Henriksen, Nils; Magyari, Melinda; Sørensen, Per S; Sellebjerg, Finn; Søndergaard, Helle B.

I: Neurology, Bind 90, Nr. 7, 2018, s. e593-e600.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Petersen, ER, Oturai, AB, Koch-Henriksen, N, Magyari, M, Sørensen, PS, Sellebjerg, F & Søndergaard, HB 2018, 'Smoking affects the interferon beta treatment response in multiple sclerosis', Neurology, bind 90, nr. 7, s. e593-e600. https://doi.org/10.1212/WNL.0000000000004949

APA

Petersen, E. R., Oturai, A. B., Koch-Henriksen, N., Magyari, M., Sørensen, P. S., Sellebjerg, F., & Søndergaard, H. B. (2018). Smoking affects the interferon beta treatment response in multiple sclerosis. Neurology, 90(7), e593-e600. https://doi.org/10.1212/WNL.0000000000004949

Vancouver

Petersen ER, Oturai AB, Koch-Henriksen N, Magyari M, Sørensen PS, Sellebjerg F o.a. Smoking affects the interferon beta treatment response in multiple sclerosis. Neurology. 2018;90(7):e593-e600. https://doi.org/10.1212/WNL.0000000000004949

Author

Petersen, Eva R ; Oturai, Annette B ; Koch-Henriksen, Nils ; Magyari, Melinda ; Sørensen, Per S ; Sellebjerg, Finn ; Søndergaard, Helle B. / Smoking affects the interferon beta treatment response in multiple sclerosis. I: Neurology. 2018 ; Bind 90, Nr. 7. s. e593-e600.

Bibtex

@article{cc25938f2079442a9ba003b85c65c990,
title = "Smoking affects the interferon beta treatment response in multiple sclerosis",
abstract = "OBJECTIVE: To investigate whether smoking in patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon beta (IFN-β) is associated with the relapse rate and whether there is an interaction between smoking and human leukocyte antigen (HLA)-DRB1*15:01, HLA-A*02:01, and the N-acetyltransferase-1 (NAT1) variant rs7388368A.METHODS: DNA from 834 IFN-β-treated patients with RRMS from the Danish Multiple Sclerosis Biobank was extracted for genotyping. Information about relapses from 2 years before the start of treatment to either the end of treatment or the last follow-up visit was obtained from the Danish Multiple Sclerosis Treatment Register. Smoking information came from a comprehensive questionnaire.RESULTS: We found that the relapse rate in patients with RRMS during IFN-β treatment was higher in smokers compared to nonsmokers, with an incidence rate ratio (IRR) of 1.20 (95{\%} confidence interval [CI] 1.021-1.416, p = 0.027) and with an IRR increase of 27{\%} per pack of cigarettes per day (IRR 1.27, 95{\%} CI 1.056-1.537, p = 0.012). We found no association or interaction with HLA and the NAT1 variant.CONCLUSION: In this observational cohort study, we found that smoking is associated with increased relapse activity in patients with RRMS treated with IFN-β, but we found no association or interaction with HLA or the NAT1 variant.",
author = "Petersen, {Eva R} and Oturai, {Annette B} and Nils Koch-Henriksen and Melinda Magyari and S{\o}rensen, {Per S} and Finn Sellebjerg and S{\o}ndergaard, {Helle B}",
note = "{\circledC} 2018 American Academy of Neurology.",
year = "2018",
doi = "10.1212/WNL.0000000000004949",
language = "English",
volume = "90",
pages = "e593--e600",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams & Wilkins",
number = "7",

}

RIS

TY - JOUR

T1 - Smoking affects the interferon beta treatment response in multiple sclerosis

AU - Petersen, Eva R

AU - Oturai, Annette B

AU - Koch-Henriksen, Nils

AU - Magyari, Melinda

AU - Sørensen, Per S

AU - Sellebjerg, Finn

AU - Søndergaard, Helle B

N1 - © 2018 American Academy of Neurology.

PY - 2018

Y1 - 2018

N2 - OBJECTIVE: To investigate whether smoking in patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon beta (IFN-β) is associated with the relapse rate and whether there is an interaction between smoking and human leukocyte antigen (HLA)-DRB1*15:01, HLA-A*02:01, and the N-acetyltransferase-1 (NAT1) variant rs7388368A.METHODS: DNA from 834 IFN-β-treated patients with RRMS from the Danish Multiple Sclerosis Biobank was extracted for genotyping. Information about relapses from 2 years before the start of treatment to either the end of treatment or the last follow-up visit was obtained from the Danish Multiple Sclerosis Treatment Register. Smoking information came from a comprehensive questionnaire.RESULTS: We found that the relapse rate in patients with RRMS during IFN-β treatment was higher in smokers compared to nonsmokers, with an incidence rate ratio (IRR) of 1.20 (95% confidence interval [CI] 1.021-1.416, p = 0.027) and with an IRR increase of 27% per pack of cigarettes per day (IRR 1.27, 95% CI 1.056-1.537, p = 0.012). We found no association or interaction with HLA and the NAT1 variant.CONCLUSION: In this observational cohort study, we found that smoking is associated with increased relapse activity in patients with RRMS treated with IFN-β, but we found no association or interaction with HLA or the NAT1 variant.

AB - OBJECTIVE: To investigate whether smoking in patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon beta (IFN-β) is associated with the relapse rate and whether there is an interaction between smoking and human leukocyte antigen (HLA)-DRB1*15:01, HLA-A*02:01, and the N-acetyltransferase-1 (NAT1) variant rs7388368A.METHODS: DNA from 834 IFN-β-treated patients with RRMS from the Danish Multiple Sclerosis Biobank was extracted for genotyping. Information about relapses from 2 years before the start of treatment to either the end of treatment or the last follow-up visit was obtained from the Danish Multiple Sclerosis Treatment Register. Smoking information came from a comprehensive questionnaire.RESULTS: We found that the relapse rate in patients with RRMS during IFN-β treatment was higher in smokers compared to nonsmokers, with an incidence rate ratio (IRR) of 1.20 (95% confidence interval [CI] 1.021-1.416, p = 0.027) and with an IRR increase of 27% per pack of cigarettes per day (IRR 1.27, 95% CI 1.056-1.537, p = 0.012). We found no association or interaction with HLA and the NAT1 variant.CONCLUSION: In this observational cohort study, we found that smoking is associated with increased relapse activity in patients with RRMS treated with IFN-β, but we found no association or interaction with HLA or the NAT1 variant.

U2 - 10.1212/WNL.0000000000004949

DO - 10.1212/WNL.0000000000004949

M3 - Journal article

C2 - 29343473

VL - 90

SP - e593-e600

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 7

ER -

ID: 216507136